Cargando…

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the treatment of metastatic non‐small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jin, Zhang, Chao, Zhong, Wen‐Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045926/
https://www.ncbi.nlm.nih.gov/pubmed/33689225
http://dx.doi.org/10.1002/cac2.12153